Cross-Sector entity
regulation is the sole category represented across all 2 tracked stories. American Society of Plastic Surgeons is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Each carries 3 original sources on average. We currently track 2 Cross-Sector stories that mention Cass Review, all published on August 13, 2026.
2 verified stories tracked
Last mentioned: Aug 13, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 2 tracked stories. American Society of Plastic Surgeons is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Each carries 3 original sources on average. We currently track 2 Cross-Sector stories that mention Cass Review, all published on August 13, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cass Review. Shared-story counts are live from our verified record — not editorial picks.
Federal funding restrictions take effect
Medicaid and CHIP stop covering puberty blockers, cross-sex hormones, and surgical procedures for minors, with a six-month taper for current hormone therapy patients.
Trump announces funding cutoff on Truth Social
President Trump called the treatments 'barbaric surgeries' and said the government would not pay for harms to minors.
Legal and compliance teams face a new federal directive ending Medicaid and CHIP coverage for minors' gender-affirming care on October 13, while states retain authority to spend their own funds. Expect litigation over CMS authority, equal protection, and Section 1557.
Pediatricians, endocrinologists, and health systems must prepare for an October 13 loss of Medicaid and CHIP reimbursement for puberty blockers, cross-sex hormones, and surgeries for minors. Current hormone therapy patients get a six-month taper, while mental health coverage remains intact.
Source: russiaherald.com · austinglobe.com
